Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

171.50 -4.24 (-2.41%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 16, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

56 57 Next >

Biogen Reports New Spinraza Data In Atrophy Patients After Incomplete Response To Novartis' Treatment ↗

July 03, 2023

Biogen Inc (NASDAQ: BIIB) announced new Spinraza (nusinersen) data that were presented at the SMA Research & Clinical Care Meeting

Via Benzinga

New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy

June 30, 2023

From Biogen Inc.

Via GlobeNewswire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

June 30, 2023

Via Benzinga

Amgen Inc. Dividend Stock Analysis ↗

June 30, 2023

The company has paid a cash dividend to shareholders every year since 2011 and has increased its dividend payments for 13 consecutive years.

Via Talk Markets

How Is The Market Feeling About Biogen? ↗

June 29, 2023

Via Benzinga

A Look Into Biogen Inc's Price Over Earnings ↗

June 27, 2023

Via Benzinga

$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much Today ↗

June 21, 2023

Via Benzinga

Is This a Sign That Biogen's Leqembi Could Obtain FDA Approval Next Month? ↗

June 23, 2023

The catalyst many Biogen investors have been waiting for may soon arrive.

Via The Motley Fool

Alleged Industrial Espionage Makes an Interesting Story ↗

June 21, 2023

We also chat about Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment.

Via The Motley Fool

5 Biotech Stocks That Could Soar Thanks To These Disruptive Healthcare Technologies ↗

June 20, 2023

Via Benzinga

Does This Signal Trouble for Biogen's New Alzheimer's Drug? ↗

June 19, 2023

Biogen is counting on Leqembi to boost its revenue growth.

Via The Motley Fool

How to Retire Rich: Biotech Stocks Edition ↗

June 18, 2023

Thanks to its enormous and practically permanent relevancies, the biotech sector offers a great avenue for retirement planning stocks.

Via InvestorPlace

Expert Ratings for Biogen ↗

June 08, 2023

Via Benzinga

2 Market-Beating Stocks With Major Catalysts on the Way ↗

June 17, 2023

Can these companies keep climbing?

Via The Motley Fool

7 Undervalued S&P 500 Stocks to Buy in June ↗

June 15, 2023

If you want to maximize your upside potential in a relatively predictable arena, these undervalued S&P 500 stocks could be for you.

Via InvestorPlace

Senator Bernie Sanders Puts Brakes on Health Agency Nominees Until Drug Pricing Issue is Addressed ↗

June 14, 2023

Senator Bernie Sanders vowed to oppose President Joe Biden's nominated candidate, Monica Bertagnolli, or any other current or future health agency nominee, to lead the National Institutes of Health...

Via Benzinga

Why Biogen Stock Is Trading Down Today ↗

June 13, 2023

Biogen Inc. (NASDAQ: BIIB) shares fell Tuesday after it was deemed that the ability of the company's Alzheimer's drug, Leqembi, to slow cognitive decline may not outweigh its risks, according to...

Via Benzinga

Methode Electronics, Brookfield Renewable Partners And Other Big Stocks Moving Lower On Tuesday ↗

June 13, 2023

U.S. stocks traded higher, with the Dow Jones rising around 100 points on Tuesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

FTC Sues To Block Microsoft-Activision Blizzard Deal, Netflix's First Sports Streaming Debut, EU Mulls Antitrust Case Against Google's Ad-Tech Business: Today's Top Stories ↗

June 13, 2023

Benzinga

Via Benzinga

Alzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare Resources ↗

June 13, 2023

Experts in Europe considering the potential use of a new Alzheimer's disease drug developed by Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) say Leqembi (lecanemab)'s ability to slow

Via Benzinga

Biogen Announces Changes to Its Board of Directors

June 12, 2023

From Biogen Inc.

Via GlobeNewswire

Macro Muddle Coming Up As Market Exceeds Expectations, Small Caps Gain Ground ↗

June 12, 2023

For the bull run to continue we need broader market participation from SMID caps.

Via Talk Markets

Prospects for Full Approval of Eisai and Biogen's Leqembi Shine Brighter after FDA Committee Vote ↗

June 12, 2023

Friday, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted unanimously that the data from Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) Phase 3 Clarity AD tria

Via Benzinga

Why Are Cruise Stocks CCL, RCL, NCLH Up Today? ↗

June 12, 2023

Cruise stocks are on the rise Monday as investors react to a positive note to clients from JPMorgan analysts and we've got the details!

Via InvestorPlace

BIIB Stock Alert: Biogen Resumes Trading With New FDA Backing ↗

June 12, 2023

Biogen (BIIB) stock is a hot topic among traders Monday as the company's share resumed trading following a halt that was in effect on Friday.

Via InvestorPlace

Nasdaq, S&P 500 Futures Signal Strong Start To Week On Hopes Of Fed Pause: Why This Analyst Is Pricing In A 20% Gain From Bear Market Low ↗

June 12, 2023

Via Benzinga

FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

June 09, 2023

From Biogen Inc.

Via GlobeNewswire

Biogen Stock Halted As It Faces Make-Or-Break Moment For Alzheimer's Treatment ↗

June 09, 2023

A panel of experts will debate the merits of Biogen's drug, Leqembi.

Via Investor's Business Daily

Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable' ↗

June 08, 2023

Senator Bernie Sanders urged the U.S.

Via Benzinga

FDA Signals Support for Eisai-Biogen Alzheimer's Drug Data Confirms Benefits For Complete Approval ↗

June 08, 2023

FDA Peripheral and Central Drugs Advisory Committee is meeting Friday (June 9) to discuss a supplemental marketing application for Leqembi (lecanemab) submitted by Eisai Co Ltd (OTC: ESALY) for...

Via Benzinga

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

56 57 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.